A framework for estimating the national economic benefits of ATP funding of medical technologies: preliminary applications to tissue engineering projects funded from 1990 to 1996, final report

[1]  D. Pennington,et al.  Heart transplantation charges: status 1 versus status 2 patients. , 1995, The Journal of Heart and Lung Transplantation.

[2]  W. Viscusi.  Valuing health care: Discounting health effects for medical decisions , 1995 .

[3]  E. Mansfield.  TECHNICAL CHANGE AND THE RATE OF IMITATION , 1961 .

[4]  Edwin Mansfield,et al.  Estimating social and private returns from innovations based on the advanced technology program:: problems and opportunities , 1996 .

[5]  J. Newhouse,et al.  Are Medical Prices Declining? , 1996 .

[6]  L. Levin,et al.  Combined Injuries-Soft Tissue Management , 1996, Clinical orthopaedics and related research.

[7]  J. Javitt,et al.  Lessening the Burden of Diabetes: Intervention Strategies , 1993, Diabetes Care.

[8]  K. Naunheim,et al.  Cost of patient follow-up after potentially curative lung cancer treatment. , 1996, The Journal of thoracic and cardiovascular surgery.

[9]  R. Bennett,et al.  Fibromyalgia and quality of life: a comparative analysis. , 1993, The Journal of rheumatology.

[10]  Rosalie T. Ruegg,et al.  Building Economics: Theory and Practice , 1990 .

[11]  D. Ferrigno,et al.  The tissue polypeptide antigen serum test in the preoperative evaluation of non-small cell lung cancer. Diagnostic yield and comparison with conventional staging methods. , 1995, Chest.

[12]  Principles of cost effectiveness analysis for the assessment of current and new therapies. , 1993, Journal of hematotherapy.

[13]  C. Miller,et al.  Mechanical ventricular assistance: an economical and effective means of treating end-stage heart disease. , 1995, The Annals of thoracic surgery.

[14]  A. Pakes,et al.  The Value of Patents as Indicators of Inventive Activity , 1986 .

[15]  R. Champlin.  Peripheral blood progenitor cells: a replacement for marrow transplantation? , 1996, Seminars in oncology.

[16]  M. Aldenderfer,et al.  Cluster Analysis. Sage University Paper Series On Quantitative Applications in the Social Sciences 07-044 , 1984 .

[17]  Glenn C. Loury,et al.  Market Structure and Innovation , 1979 .

[18]  R. Ratner,et al.  Hospitalization and expenditures for the treatment of general medical conditions among the U.S. diabetic population in 1991. , 1996, The Journal of clinical endocrinology and metabolism.

[19]  O. Böstman,et al.  Absorbable devices in the fixation of fractures. , 1996, The Journal of trauma.

[20]  O. Böstman,et al.  Impact of the use of absorbable fracture fixation implants on consumption of hospital resources and economic costs. , 1991, The Journal of trauma.

[21]  Frank A. Sloan,et al.  Valuing health care : costs, benefits, and effectiveness of pharmaceuticals and other medical technologies , 1995 .

[22]  O. Böstman.  Metallic or absorbable fracture fixation devices. A cost minimization analysis. , 1996, Clinical orthopaedics and related research.

[23]  Parsons Vl,et al.  Current estimates from the National Health Interview Survey. United States, 1985. , 1986, Vital and health statistics. Series 10, Data from the National Health Survey.

[24]  Rosalie Ruegg.  Guidelines for economic evaluation of the Advanced Technology Program , 1996 .

[25]  Frank A. Sloan,et al.  Valuing health care , 1996 .

[26]  P. Bossuyt,et al.  Choosing a strategy for the diagnostic management of suspected scaphoid fracture: a cost-effectiveness analysis. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  Jennifer F. Reinganum.  The timing of innovation: Research, development, and diffusion , 1989 .

[28]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[29]  J. Feldman,et al.  Vital and health statistics. Current estimates from the National Health Interview Survey, 1988. , 1989, Vital and health statistics. Series 10, Data from the National Health Survey.

[30]  J. Mauskopf,et al.  Estimating the value of avoiding morbidity and mortality from foodborne illnesses. , 1991, Risk analysis : an official publication of the Society for Risk Analysis.

[31]  H. Brown,et al.  Validity of Euroqol--a generic health status instrument--in patients with rheumatoid arthritis. Economic and Health Outcomes Research Group. , 1994, British journal of rheumatology.

[32]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[33]  R. Evans.  Organ transplantation and the inevitable debate as to what constitutes a basic health care benefit. , 1993, Clinical transplants.

[34]  Michael J. Moore,et al.  Doubling the Estimated Value of Life: Results Using New Occupational Fatality Data , 1988 .

[35]  Michael J. Moore,et al.  The Quantity-Adjusted Value of Life , 1988 .

[36]  Manuel Trajtenberg,et al.  Economic Analysis of Product Innovation: The Case of CT Scanners , 1990 .

[37]  D. Andrulis,et al.  Assessing medical technologies. , 1978, Bulletin of the New York Academy of Medicine.

[38]  Jeanne W. Powell.  The ATP ’ s Business Reporting System : A Tool for Economic Evaluation , 1998 .

[39]  L. Fourt,et al.  Early Prediction of Market Success for New Grocery Products , 1960 .

[40]  John Beath,et al.  Strategic R&D Policy , 1989 .

[41]  D. Feeny,et al.  Utilities and Quality-Adjusted Life Years , 1989, International Journal of Technology Assessment in Health Care.

[42]  K. McPherson,et al.  Measuring the impact of menopausal symptoms on quality of life. , 1993, BMJ.

[43]  Robert A. Peterson,et al.  Models for innovation diffusion , 1985 .

[44]  Anne C. Haddix,et al.  Prevention effectiveness : a guide to decision analysis and economic evaluation , 1996 .

[45]  O. Böstman.  Economic Considerations on Avoiding Implant Removals after Fracture Fixation by Using Absorbable Devices , 1994, Scandinavian journal of social medicine.

[46]  C. Vangsness,et al.  Review of outcome instruments for evaluation of anterior cruciate ligament reconstruction. , 1995, Bulletin (Hospital for Joint Diseases (New York, N.Y.)).

[47]  Robert Fabian,et al.  Valuing health for policy : an economic approach , 1995 .

[48]  Daniel M. Violette,et al.  The value of reducing risks of death: A note on new evidence , 1989 .

[49]  D. Shaw,et al.  External fixation for tibial fractures: clinical results and cost effectiveness. , 1995, Journal of the Royal College of Surgeons of Edinburgh.

[50]  D. W. Jackson,et al.  Biologic Incorporation of Allograft Anterior Cruciate Ligament Replacements , 1996, Clinical orthopaedics and related research.

[51]  O. Böstman,et al.  Metallic or absorbable implants for ankle fractures: a comparative study of infections in 3,111 cases. , 1996, Acta orthopaedica Scandinavica.

[52]  Tom Lee,et al.  Market Structure and Innovation: A Reformulation , 1980 .

[53]  D. Blaise,et al.  Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness. , 1994, Bone Marrow Transplantation.